NextCure (NASDAQ:NXTC) Stock: Insider Adar1 Capital Management, Llc Acquires 5,626 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 5,626 shares of NextCure stock in a transaction on Friday, October 23rd. The shares were purchased at an average price of $4.83 per share, for a total transaction of $27,173.58. Following the acquisition, the insider directly owned 728,045 shares in the company, valued at approximately $3,516,457.35. This trade represents a 0.78% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, October 27th, Adar1 Capital Management, Llc bought 3,553 shares of NextCure stock. The stock was purchased at an average cost of $5.10 per share, with a total value of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc bought 1,672 shares of NextCure stock. The stock was purchased at an average price of $5.03 per share, with a total value of $8,410.16.
• On Friday, July 31st, Adar1 Capital Management, Llc bought 36,303 shares of NextCure stock. The stock was purchased at an average price of $4.94 per share, with a total value of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc purchased 292,850 shares of NextCure stock. The shares were purchased at an average price of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The shares were purchased at an average price of $5.00 per share, for a total transaction of $17,050.00.

NextCure Price Performance

NXTC stock traded up $0.50 during midday trading on Tuesday, hitting $5.72. The stock had a trading volume of 142,082 shares. The business has a 50-day moving average of $6.11 and a two-hundred day moving average of $7.99. NextCure, Inc. has a 52-week low of $1.55 and a 52-week high of $15.74.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($1.95) by ($0.85).

Institutional Inflows and Outflows

A hedge fund recently raised its position in NextCure stock. Renaissance Technologies LLC grew its stake in NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,534 shares of the company’s stock after acquiring an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 at the end of the most recent quarter. 42.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NXTC. HC Wainwright reiterated a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings cut shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, NextCure has a consensus rating of “Hold” and a consensus price target of $19.00.

NextCure Company Profile

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.